If we believe normalcy will return to the U.S. financial system, this investing plan could give outsized returns.
Here's what to avoid.
Software work management firm MNDY is sporting some bullish charts. Let's check the price targets ahead.
Insider buying by the new CEO of this buyer of biopharmaceutical royalties, puts this name on my radar.
The AI frenzy is taking a rest, and the number of stocks that are attracting speculative interest is very slim.
Let's review the charts of this cybersecurity name.
This balance sheet needs a lot of work.
Here's why we would wait for better buying opportunities.
The technical signals aren't yielding a clear answer to that question.
I believe in the old saying that 'news follows the tape.'